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Abstract
Background: Little is known about management and prognosis for malignant head & neck paragangliomas. We
reviewed records of these patients to determine optimal treatment strategies.
Methods: We reviewed 113 cases of head & neck paragangliomas treated at our institution from 1970 to 2005.
Nineteen patients were included in the study. All had primary surgical treatment at another institution. Metastatic
disease was treated with radiation, chemotherapy, or both. Survival and complications were evaluated. P values
were determined by Fischer’s exact test.
Results: All patients treated with chemotherapy and radiation age ≥ 40 years had disease progression. Of the
patients < 40, two had stable disease; one had regression of disease with treatment. Patients without disease
progression had better prognosis and were alive at last follow-up.
Conclusions: Clinical benefit was derived from aggressive treatment. However, careful consideration of the risks of
observation versus intensive therapy should be undertaken when managing these patients.
Background
Paragangliomas (PGs) represent rare tumors of neuroen-
docrine origin, are comprised of sustenacular and chief
cells in an organoid or Zellballen pattern and commonly
arise in various locations in the head and neck [1].
Malignant PGs are defined by presence of pathologically
confirmed PG cells in lymph nodes or in distant organs,
rather than by the histological features of the primary
tumor [2]. Only a small percentage of patients ultimately
develop metastatic disease, and malignant PGs are
believed to represent only 4% to 15% of all head and
neck PGs [3-5]. When considering the major classes of
PG sub-types, rates of malignancy are believed to be 2 -
4% for jugular-tympanic tumors, 6% for carotid body
tumors, and 16 - 19% for vagal tumors [6,7].
For patients identified with regionally metastatic dis-
ease, radiation after primary surgical treatment offers
the best prognosis [4]. Patients with metastases to dis-
tant organs, most commonly lung and liver, are often
treated with systemic therapy [8]. However, due to the
rarity of these lesions, optimal treatment strategies have
not been defined to date. In particular, most studies of
chemotherapy for malignant PG have focused on thor-
acic and abdominal PG, which have biological behaviors
distinct from head and neck PG [9]. Abdominal, pelvic,
and thoracic PGs originate in the sympathetic auto-
nomic nervous system ganglia. They are frequently asso-
ciated with a norepinephrine biochemical phenotype. A
significant number of sympathetic PGs are malignant.
Conversely, head and neck PGs originate in parasympa-
thetic autonomic nervous system ganglia. Typically, they
are hormonally silent and are rarely malignant.
To define the outcomes and optimal treatment strate-
gies of malignant head and neck PG, we reviewed a sin-
gle institution’s 35-year experience with these lesions.
Methods
All patients with malignant PG of the head and neck
treated at the University of Texas MD Anderson Cancer
Center (MDACC) from 1970 to 2005 were reviewed
after IRB approval was obtained. Pathology, radiologic
imaging, operative reports, and all clinical notes were
reviewed. Patients referred to our institution without
complete documentation were excluded from our study.
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Results
Epidemiologic Data
We identified 113 patients with cervical PGs using insti-
tutional diagnosis codes, 23 (18%) of whom had regional
or distant metastases. Summary statistics are presented
in Table 1. Four patients were excluded because outside
hospital records were incomplete or unavailable. Thus,
the records of 19 patients were available for this
analysis.
The mean age of the patients within our cohort
was 35 (range: 16 - 62), with 10 (53%) patients above
40 years of age. All patients in our study had their pri-
mary surgery at outside hospitals and were referred to
MDACC for recurrent or progressive disease. Our sam-
ple consisted of 10 patients (53%) with carotid body
tumors, 6 (32%) with jugulotympanic tumors and 3 with
other tumors (Table 1). Of note, no patients within our
series presented with metastatic disease due to a pri-
mary vagal nerve PG. Bone metastases occurred most
commonly in the setting of jugulotympanic tumors,
whereas carotid body tumors had a predilection for both
lung and bone metastases (Table 2). Figures 1 and 2 are
representative radiographic images obtained from
patients in this series.
Review of patient records was notable for 3 patients
with a family history of PG. One patient was known to
have a functional tumor that led to hypertension. This
patient had elevated levels of dopamine, normetanephr-
ine and chromogranin A. One patient was known to
have von Hippel-Lindau syndrome. Two patients had
bilateral carotid body disease, though contralateral dis-
ease was discovered in both patients several years after
carotid body tumor resection. At the time of diagnosis,
Table 1 Summary of gender, histology, and tumor
characteristics for patients in this series
Summary Statistics
(n = 19)
Age (mean) 35
Gender
Men 13 69%)
Women 6 (32%)
Primary Site
Carotid Body 10 (53%)
Jugulotympanic 6 ( 32%)
Other 3 (16%)
Metastatic Sites
Lymph Nodes 5 (26%)
Liver 5 (26%)
Lung 7 (37%)
Bone 13 (68%)
Other 12 (63%)
Table 2 Summary of the extent of disease identified over the course of follow-up for patients in this series
Tumor characteristics for patients included in this study
Metastatic Sites
Patient Primary Site Bone Neck/Regional Nodes Liver Lung Brain Spleen Eye
1 Carotid body + +
2 Middle fossa/Cavernous sinus +
3 Jugulotympanic + + +
4 Jugulotympanic + +
5 Carotid body + +
6 Carotid body + +
7 Carotid body +
8 Jugulotympanic + + +
9 Carotid body + + +
10 Jugulotympanic +
11 Carotid body + + + +
12 Jugulotympanic +
13 Carotid body +
14 Carotid body + + +
15 Carotid body + +
16 Jugulotympanic +
17 Carotid body + +
18 Carotid body/Glomus vagale +
19 Parotid + +
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with PGs.
Treatment
We examined the treatment approaches for patients
within our cohort, including chemotherapy and external
beam radiation therapy (EBRT) (Table 3). The most
common mode of therapy was palliative radiation ther-
apy to the spine, pelvis, and areas of local recurrence.
Fourteen patients (74%) in our series received radiation
and 11 patients (58%) were treated with chemotherapy.
A total of 10 patients (53%) received both chemotherapy
and radiation (Figure 3).
The most commonly used chemotherapy regimen was
cyclophosphamide, vincristine, doxorubicin, and dacar-
bazine (CVAD), but this was only used in 4 patients
(21%). Other chemotherapy regimens are presented in
Table 3. Few treatment-related complications were
reported (27%). One patient developed uncomplicated
neutropenia and one patient treated with an adriamy-
cin-based regimen developed alopecia.
Radiation doses varied widely, with patients receiving
total doses of 55 Gy to 143 Gy for local control and
management of metastatic sites, with 2 patients having
received multiple courses of EBRT (Table 3). One
patient who was treated with two courses of cervical
irradiation developed skin sloughing in the setting of
progressive disease. A summary of all treatments and
outcomes is presented in Table 4.
Outcomes
Overall, five-year survival of patients above 40 years old
with malignant PGs was 60% (Figure 4). Regressive and
stable disease was more common in patients diagnosed
before age 40, and age less than 40 years portended for
improved prognosis as well. Additionally, female patients
tended to have better responses to treatment compared
to men (Tables 3 and 4).
Of the 14 patients treated with EBRT, 12 developed
progressive disease despite therapy. One patient experi-
enced stable disease after radiation (Tables 3 and 4). For
Figure 1 Representative magnetic resonance image revealing bone metastasis indicated by the white arrow.
Figure 2 Representative computed tomographic image
revealing liver metastases in a PG patient.
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the 10 patients receiving combination therapy, 6 (67%)
had disease progression, 2 (22%) had stable disease, and
1 (11%) experienced regression. Table 4 provides a sum-
mary of outcome data stratified by treatment type.
In general, no treatment or combination of treatments
demonstrated therapeutic superiority. However, patients
who received radiation therapy after primary surgical
treatment experienced more favorable outcomes com-
pared to patients who did not receive radiation to con-
trol local disease (P = .05). During the entire follow-up
period, 9 patients (47%) were found to have disease
spread either to regional nodes or surrounding struc-
tures. Follow-up data revealed a 5-year survival of 84%
and 10-year survival of 53% (Figure 5).
Discussion
Due to their rarity, metastatic head and neck PGs
remain clinically challenging. Our data reveal that the
management and progression of malignant head and
neck PGs is complicated and highly variable. These
results suggest that young patients (age ≤ 40) are more
likely to demonstrate a favorable response to therapy.
Additionally, female patients tended to have more favor-
able responses, though this trend was not statistically
s i g n i f i c a n t .W h i l es p e c i f i cr e g i m e n sc a n n o tb ep r e -
scribed, the aggressive tumors may be treated with mul-
tiple systemic agents, though strict follow-up to assess
progression in the absence of treatment also appears
appropriate given the outcomes of treatments detailed
herein.
Table 3 Summary of individual treatments utilized over the course of follow-up at MDACC for patients in this series
Treatments, side-effects and responses for patients included in this study
Gender Radiation Chemotherapy
Received Dose
(Gy)
Side Effects Response Received Regimen Side Effects Response
F Y 143 Skin
sloughing
Progression Y CCNU, Adriamycin Alopecia Progression
MN –– – N –– –
F Y 55 Otalgia Progression N –– –
M Y N/A N/A Progression Y VP-16, Cisplatin N/A Progression
F Y 68 Mucositis Progression Y DTIC, Adriamycin, Mesna, Ifosfamide N/A Progression
F Y N/A N/A Progression Y CDDP, VP-16 None Progression
F Y N/A N/A Regression Y N/A N/A Regression
M Y 90 N/A Progression Y CVAD Febrile neutropenia, N/
V
Stable
F Y 39 N/A N/A Y CVAD N/A N/A
M Y 60 None Progression Y Adriamycin, Cytoxan, VP-16, Cisplatin,
FTI
None Progression
FN –– – Y CVAD N/A N/A
M Y N/A N/A Progression N –– –
FN –– – N –– –
F Y N/A N/A Stable N –– –
F Y N/A N/A Progression Y Taxol, Cytoxan, Adriamycin, DTIC None Stable
F Y N/A N/A Progression N –– –
FN –– – N –– –
FN –– – N –– –
F Y N/A Mucositis Progression Y CVAD Alopecia Progression
N/A implies the data are unknown, ‘-’ implies the patients did not receive the therapy. (Summary of abbreviations: CCNU: Lomustine; VP-16: Etoposide; DTIC:
Dacarbazine; CDDP: Cisplatin; CVAD: Cyclophosphamide, Vincristine, Doxorubicin, and Dacarbazine; FTI: Farnesyl transferase inhibitor; N/V: Nausea/Vomiting).
Figure 3 The distribution of patients receiving radiation,
chemotherapy and combination therapy.
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Summary of tumor characteristics, treatment and responses
Primary Site Metastatic Sites Treatment Response
Carotid Body Jugulo-tympanic Other Liver Lung Bone Other Radiation Chemotherapy Both Progression Stable Regression
By Gender
Men 1 (17%) 4 (67%) 1 (17%) 1 (17%) - 6 (100%) 3 (50%) 5 (83%) 4 (67%) 4 (67%) 5 (83%) 1 (17%) -
Women 9 (69%) 2 (15%) 2 (15%) 4 (31%) 7 (54%) 7 (54%) 9 (69%) 9 (69%) 7 (54%) 6 (46%) 5 (38%) 4 (31%) 1 (8%)
By Age at Presentation
> 40 3 (33%) 3 (33%) 3 (33%) 2 (22%) 4 (44%) 6 (67%) 6 (67%) 7 (78%) 5 (56%) 5 (56%) 7 (78%) 1 (11%) -
< = 40 7 (70%) 3 (30%) - 3 (33%) 3 (33%) 7 (78%) 6 (60%) 7 (70%) 6 (60%) 5 (50%) 3 (30%) 4 (40%) 1 (10%)
By Primary Site
Carotid Body 10 - - 3 (30%) 5 (50%) 6 (60%) 8 (80%) - - - 3 (30%) 3 (30%) 1 (10%)
Jugulotympanic - 6 - 2 (33%) 1 (17%) 5 (83%) 3 (50%) - - - 5 (83%) 1 (17%) -
Other - - 3 - 1 (33%) 2 (67%) 1 (33%) - - - 2 (67%) 1 (33%) -
By Treatment
Radiation 7 (70%) 6 (100%) 1 (33%) - - - - 14 - - 12 (92%) 1 (8%) 0 (0%)
Chemotherapy 7 (70%) 3 (50%) 1 (33%) - - - - - 11 - 6 (55%) 2 (18%) 1 (9%)
Both 6 (60%) 3 (50%) 1 (33%) - - - - - - 10 6 (60%) 2 (20%) 1 (10%)
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8Our data reflect the results of a previous study per-
formed at MDACC where, in a group of 13 patients
with malignant PGs (only two patients with primary
head and neck PGs), 92% achieved at least stable disease
on CVAD [10]. This compares to the use of a combina-
tion of cyclophosphamide, vincristine, and dacarbazine
(CVD) studied in the setting of malignant PGs, where
complete response was achieved in only 11% of patients,
partial response in 44% of patients, and stable disease in
22% of patients [11]. A newer approach to therapy has
been the use of radio-iodinated metaiodobenzylguani-
dine, a norepinephrine analog that has yielded a 75%
5-year survival with a majority of patients achieving at
least a partial response to therapy [12-14].
Historically, external beam radiation has assumed a
palliative role in the treatment of spinal and other bone
metastasis [15]. None of the 14 patients receiving radia-
tion experienced neurologic sequelae, a recognized com-
plication in the palliative treatment of bone disease.
Though not statistically significant, radiation appeared
to be more effective in younger patients. These findings
are in line with prior studies where radiation has been
described for bony metastasis, though no evidence of a
benefit to younger patients was found [16].
During the entire follow-up period, 7 patients (41%)
were found to have local disease spread either to regional
nodes or surrounding structures. This compares to the
aforementioned study conducted by Lee et al, which
revealed that 69% of patients with malignant PG experi-
enced regional spread [4]. Though only 50% of patients
with regional metastasis eventually develop distant spread
of disease, these patients typically do not have favorable
outcomes. High rates of local spread and poor response
to therapy complicate management in these patients.
Based upon data from the National Cancer Database,
Lee et al reported on patients with both regional and dis-
tant spread from head and neck PG and found a 5-year
survival of 11.8% [4]. More recently, a 44% 5-year survival
was observed in patients with metastatic PGs undergoing
radiation and chemotherapy [12]. In a study performed by
Fitzgerald et al, patients with pulmonary metastases
experienced significantly shortened survival compared to
patients with metastases to other sites. Our series revealed
an 84% five-year survival that is likely attributable to the
head and neck origin of disease in these patients compared
to pheochromocytoma. Additionally, previously reported
studies involve clinical trials with patients that were likely
to present with more advanced disease than those
reported in this series. What requires further study is the
impact of germline mutations in the SDH genes on overall
outcomes. Genotype-phenotype correlations have identi-
fied distinct mutations that pre-dispose to malignant
lesions, findings that may offer novel therapies that specifi-
cally target these malignant phenotypes [17].
Though the metastatic potential of this tumor remains
unclear, distant spread is an extremely rare event [18].
Therefore, regional lymphadenectomy, as well as adju-
vant radiation with primary surgical resection for meta-
static PG, remains the optimal treatment modality. Data
from the National Cancer Database revealed that 34% of
patients with regional metastasis received adjuvant
radiation, though the distribution of patients receiving
radiation increases with time [4]. Due to the inability to
detect aggressive disease, surgical resection, radiation
therapy, or observation without adjuvant therapy is cur-
rently the standard of care for the tumors that do not
exhibit aggressive characteristics.
The present management of malignant head and neck
PGs are based largely on retrospective data. Due to the
rarity of this disease process, prospective data are
Figure 4 Kaplan-Meier overall survival curves for patients
based on age at diagnosis.
Figure 5 Kaplan-Meier overall survival curves over 10 years for
patients with malignant head & neck paragangliomas.
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patients presented complicates the ability to compare
the efficacy of any particular management approach and
compromises the completeness of the patient records.
Additionally, due to the small number of patients pre-
senting with head and neck PGs, some of the trends
described here were unable to achieve statistical signifi-
cance. Based on our observations we have developed a
treatment algorithm that guides, at a very high level, the
diagnostic and treatment options for patients. However,
lacking controlled trial data prevent the recommenda-
tion of specific therapeutic modalities or types of ther-
apy within each category. Figure 6 presents this
algorithmic overview.
Conclusions
What remains clear is that aggressive treatment of
regional and distant disease with radiation therapy
and systemic chemotherapy may be a viable option to
achieve disease control in a large number of patients.
In our study, 33% of patients experienced clinical
benefit with aggressive therapy. Therefore, the risks
and benefits of treatments should be carefully
weighed against the possibility of close follow-up
with treatments directed at controlling symptoms.
Further investigation will be needed to capture the
indolent and complex course these tumors typically
experience.
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